Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Net Income towards Common Stockholders: 2014-2025

Historic Net Income towards Common Stockholders for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $73.1 million.

  • Ascendis Pharma A's Net Income towards Common Stockholders fell 32.86% to $73.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.2 million, marking a year-over-year decrease of 35.32%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Net Income towards Common Stockholders stood at $73.1 million, which was up 60.51% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Net Income towards Common Stockholders ranged from a high of $176.6 million in Q3 2023 and a low of -$211.6 million during Q4 2022.
  • Over the past 3 years, Ascendis Pharma A's median Net Income towards Common Stockholders value was $108.9 million (recorded in 2024), while the average stood at $80.1 million.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's Net Income towards Common Stockholders showed a top increase of 282.13% in 2022 and a maximum decrease of 85.96% in 2022.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Net Income towards Common Stockholders stood at -$121.3 million in 2021, then plummeted by 74.41% to -$211.6 million in 2022, then surged by 55.07% to -$95.1 million in 2023, then surged by 56.77% to -$41.1 million in 2024, then crashed by 32.86% to $73.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at $73.1 million for Q3 2025, versus $45.6 million for Q2 2025 and $99.6 million for Q1 2025.